98%
921
2 minutes
20
Background: Accurate preoperative assessment of axillary lymph node metastasis (ALNM) in breast cancer is crucial for guiding treatment decisions. This study aimed to develop a deep-learning radiomics model for assessing ALNM and to evaluate its impact on radiologists' diagnostic accuracy.
Methods: This multicenter study included 866 breast cancer patients from 6 hospitals. The data were categorized into training, internal test, external test, and prospective test sets. Deep learning and handcrafted radiomics features were extracted from ultrasound images of primary tumors and lymph nodes. The tumor score and LN score were calculated following feature selection, and a clinical-radiomics model was constructed based on these scores along with clinical-ultrasonic risk factors. The model's performance was validated across the 3 test sets. Additionally, the diagnostic performance of radiologists, with and without model assistance, was evaluated.
Results: The clinical-radiomics model demonstrated robust discrimination with AUCs of 0.94, 0.92, 0.91, and 0.95 in the training, internal test, external test, and prospective test sets, respectively. It surpassed the clinical model and single score in all sets (P < .05). Decision curve analysis and clinical impact curves validated the clinical utility of the clinical-radiomics model. Moreover, the model significantly improved radiologists' diagnostic accuracy, with AUCs increasing from 0.71 to 0.82 for the junior radiologist and from 0.75 to 0.85 for the senior radiologist.
Conclusions: The clinical-radiomics model effectively predicts ALNM in breast cancer patients using noninvasive ultrasound features. Additionally, it enhances radiologists' diagnostic accuracy, potentially optimizing resource allocation in breast cancer management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12065944 | PMC |
http://dx.doi.org/10.1093/oncolo/oyaf090 | DOI Listing |
Stem Cell Rev Rep
September 2025
Paris Cité University, INSERM UMR-S 970, Paris Cardiovascular Research Centre, Paris, France.
Endothelial Colony-Forming Cells (ECFCs) are recognized as key vasculogenic progenitors in humans and serve as valuable liquid biopsies for diagnosing and studying vascular disorders. In a groundbreaking study, Anceschi et al. present a novel, integrative strategy that combines ECFCs loaded with gold nanorods (AuNRs) to enhance tumor radiosensitization through localized hyperthermia.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Ann Surg Oncol
September 2025
Department of Surgery, Division of Surgical Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Ann Surg Oncol
September 2025
Department of General Surgery, Abdulkadir Yuksel State Hospital, Gaziantep, Turkey.
Breast Cancer Res Treat
September 2025
Department of Pharmacy, Duke University Hospital, Durham, NC, USA.
Purpose: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), including patients with brain metastases (BrM) or leptomeningeal disease (LMD). This study assesses the efficacy and safety of sequential sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) in MBC and impact on chemotherapy (CTX).
Methods: This is a single-center, retrospective, cohort study in adult patients with HR + , HER2-negative, or low MBC who received T-DXd and/or SG.